TASOR2

Across TCGA pan-cancer cohorts, TASOR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TASOR2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TASOR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TASOR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where TASOR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.380	1.000	.008	16	view →
UCEC	OS	Median	III,IV	0.903	0.554	.020	12	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
GBM	OS	Tertile	All	0.899	0.552	.026	4	view →
CCRCC	OS	Median	All	0.937	0.756	.019	4	view →
LSCC	OS	Median	III,IV	0.766	0.932	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TASOR2–HNSC (OS)

Open the HNSC breakdown →